189 related articles for article (PubMed ID: 35190304)
1. Real world utilization of Dalbavancin at a rural community emergency department.
Dolan A; Kuge E; Bremmer E; Dietrich T; Santarelli A; Ashurst J
Am J Emerg Med; 2022 Apr; 54():253-256. PubMed ID: 35190304
[TBL] [Abstract][Full Text] [Related]
2. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS.
Valerio M; Veintimilla C; Rodríguez C; de la Villa S; Sánchez-Somolinos M; Cerezales M; Crespo C; Rodríguez S; Adán I; Chamorro E; Rosselló I; Muñoz P
J Med Econ; 2023; 26(1):463-472. PubMed ID: 36950932
[TBL] [Abstract][Full Text] [Related]
7. A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study.
Pascale R; Maccaro A; Mikus E; Baldassarre M; Tazza B; Esposito F; Rinaldi M; Tenti E; Ambretti S; Albertini A; Viale P; Giannella M; Bartoletti M
J Glob Antimicrob Resist; 2022 Sep; 30():390-394. PubMed ID: 35878780
[TBL] [Abstract][Full Text] [Related]
8. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
Marcellusi A; Bini C; Andreoni M; Sarmati L; Espin J; Horcajada JP; Czypionka T; Andretta D; Sciattella P; Favato G; Mennini FS
Clin Drug Investig; 2020 Apr; 40(4):305-318. PubMed ID: 32034687
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
[TBL] [Abstract][Full Text] [Related]
12. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
[TBL] [Abstract][Full Text] [Related]
14. Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.
Oliva A; Carbonara S; Cianci V; Crapis M; Di Domenico EG; Falcone M; Galardo G; Durante-Mangoni E; Venditti M
Expert Rev Anti Infect Ther; 2023; 21(7):703-721. PubMed ID: 37227028
[TBL] [Abstract][Full Text] [Related]
15. Descriptive evaluation of patients receiving one-time intravenous vancomycin doses at a large academic medical center emergency department.
Schuchter K; Shuler Truoccolo DM; Wilson WS; Anton G
Am J Emerg Med; 2024 Mar; 77():177-182. PubMed ID: 38157592
[TBL] [Abstract][Full Text] [Related]
16. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
17. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
18. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
[TBL] [Abstract][Full Text] [Related]
20. Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series.
Evins C; Lancaster H; Schnee AE
Ann Clin Microbiol Antimicrob; 2022 Apr; 21(1):16. PubMed ID: 35473711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]